ESTRO 2024 - Abstract Book

S2502

Clinical - Urology

ESTRO 2024

Conclusion:

Hypofractionated chemoradiotherapy for bladder preservation showed a similar acute and late toxicity profile as compared to conventionally fractionated chemoradiotherapy. The toxicity profile with HFRT was acceptable in spite of combining it with concurrent gemcitabine and pelvic radiotherapy. Early outcomes for cancer control and survival were similar between the two fractionation schedules.

Keywords: Ca Bladder, Fractionation, Adaptive Radiotherapy

References:

1. Choudhury A, Porta N, Hall E, Song YP, Owen R, MacKay R, West CML, Lewis R, Hussain SA, James ND, Huddart R, Hoskin P; BC2001 and BCON investigators. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol. 2021 Feb;22(2):246-255. doi: 10.1016/S1470-2045(20)30607-0. PMID: 33539743; PMCID: PMC7851111. 2. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA; BC2001 Investigators. Radiotherapy with or without chemotherapy in muscle invasive bladder cancer. N Engl J Med. 2012 Apr 19;366(16):1477-88. doi: 10.1056/NEJMoa1106106. PMID: 22512481. 3. Song YP, Mistry H, Irlam J, Valentine H, Yang L, Lane B, West C, Choudhury A, Hoskin PJ. Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1407-1415. doi: 10.1016/j.ijrobp.2021.03.001. Epub 2021 Mar 6. PMID: 33689854.

2190

Digital Poster

NTCP modeling for rectal complication based on variable RBE-weighted proton dose for prostate cancer

Hiromi Baba 1,2 , Shohei Mikasa 1 , Kenji Hotta 1 , Takashi Hanada 3 , Hidenobu Tachibana 1